Seelos Historical Income Statement
SEEL Stock | USD 0.30 0.03 9.09% |
Historical analysis of Seelos Therapeutics income statement accounts such as Gross Profit of 2.3 M, Other Operating Expenses of 23.6 M, Research Development of 31.6 M or Total Operating Expenses of 22.6 M can show how well Seelos Therapeutics performed in making a profits. Evaluating Seelos Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Seelos Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Seelos Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Seelos Therapeutics is a good buy for the upcoming year.
Seelos |
About Seelos Income Statement Analysis
Seelos Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Seelos Therapeutics shareholders. The income statement also shows Seelos investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Seelos Therapeutics Income Statement Chart
Seelos Therapeutics Income Statement is one of the three primary financial statements used for reporting Seelos's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Seelos Therapeutics revenue and expense. Seelos Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Seelos Therapeutics' Net Interest Income is quite stable compared to the past year. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Seelos Therapeutics. It is also known as Seelos Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Seelos Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Seelos Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Seelos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy Seelos Stock please use our How to buy in Seelos Stock guide.At this time, Seelos Therapeutics' Net Interest Income is quite stable compared to the past year.
2010 | 2023 | 2024 (projected) | Extraordinary Items | 691K | 621.9K | 552.8K | Non Recurring | 8.3M | 7.4M | 6.6M |
Seelos Therapeutics income statement Correlations
Click cells to compare fundamentals
Seelos Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Seelos Therapeutics income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 417K | 45K | 343K | (2.8M) | 57K | 54.2K | |
Interest Expense | 29K | 164K | 1.6M | 14K | 75K | 71.3K | |
Selling General Administrative | 7.6M | 7.8M | 15.0M | 12.3M | 12.6M | 8.7M | |
Other Operating Expenses | 29.7M | 18.8M | 61.7M | 70.9M | 42.7M | 23.6M | |
Operating Income | (29.7M) | (18.8M) | (61.7M) | (70.9M) | (40.5M) | (38.5M) | |
Ebit | (29.7M) | (18.8M) | (61.7M) | (70.9M) | (40.5M) | (38.5M) | |
Research Development | 22.6M | 11.0M | 46.6M | 58.6M | 30.1M | 31.6M | |
Ebitda | (29.3M) | (18.7M) | (61.3M) | (73.8M) | (40.4M) | (38.4M) | |
Total Operating Expenses | 29.7M | 18.8M | 61.7M | 70.9M | 42.6M | 22.6M | |
Net Income | (50.4M) | (19.2M) | (67.5M) | (76.1M) | (37.9M) | (36.0M) | |
Income Tax Expense | (497K) | 119K | 1.5M | 2.6M | 3.0M | 3.1M | |
Income Before Tax | (50.9M) | (19.1M) | (66.0M) | (73.5M) | (37.9M) | (36.0M) | |
Total Other Income Expense Net | (21.1M) | (342K) | (4.4M) | (2.6M) | 2.6M | 2.7M | |
Net Income From Continuing Ops | (51.3M) | (19.1M) | (66.0M) | (73.5M) | (37.9M) | (39.8M) | |
Non Operating Income Net Other | (70K) | (21.5M) | (178K) | (2.6M) | (2.3M) | (2.2M) | |
Net Income Applicable To Common Shares | (51.3M) | (19.1M) | (66.0M) | (73.5M) | (66.2M) | (62.9M) | |
Net Interest Income | 122K | (119K) | (1.5M) | 107K | 123K | 129.2K | |
Interest Income | 151K | 45K | 113K | 121K | 198K | 122.5K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Seelos Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Seelos Therapeutics' short interest history, or implied volatility extrapolated from Seelos Therapeutics options trading.
Currently Active Assets on Macroaxis
When determining whether Seelos Therapeutics is a strong investment it is important to analyze Seelos Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Seelos Therapeutics' future performance. For an informed investment choice regarding Seelos Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Seelos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy Seelos Stock please use our How to buy in Seelos Stock guide.Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Seelos Stock analysis
When running Seelos Therapeutics' price analysis, check to measure Seelos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seelos Therapeutics is operating at the current time. Most of Seelos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seelos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seelos Therapeutics' price. Additionally, you may evaluate how the addition of Seelos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Seelos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seelos Therapeutics. If investors know Seelos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seelos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.73) | Revenue Per Share 0.45 | Return On Assets (1.80) | Return On Equity (5.84) |
The market value of Seelos Therapeutics is measured differently than its book value, which is the value of Seelos that is recorded on the company's balance sheet. Investors also form their own opinion of Seelos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seelos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seelos Therapeutics' market value can be influenced by many factors that don't directly affect Seelos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seelos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seelos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seelos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.